Risks of pelvic inflammatory disease and bacterial vaginosis in adenomyosis patients using levonorgestrel intrauterine device or oral norethindrone. [PDF]
Niu SY, Yi YC, Shih YH, Tseng JJ.
europepmc +1 more source
Update in Women’s Health for the General Internist [PDF]
Eleanor Bimla Schwarz +3 more
core +1 more source
Levonorgestrel-releasing intrauterine device treatment in heavy menstrual bleeding: Correlation with endometrial pathology and quality of life. [PDF]
Kolcu SA, Kara E, Yıldız E, Çetin A.
europepmc +1 more source
Considerations for Menstrual Suppression in Patients With Hematologic Malignancies. [PDF]
Veeravalli S +3 more
europepmc +1 more source
Efficacy and Outcomes of the Hormone-Releasing Levonorgestrel-Intrauterine System for Adenomyosis Treatment. [PDF]
Pragash V, Khakhar A.
europepmc +1 more source
Ranking prescribed pharmaceuticals in terms of environmental risk: inclusion of hospital data and the importance of regular review [PDF]
De Souza +20 more
core +1 more source
A Study of the Effect of the Levonorgestrel Intrauterine System on the Management of Abnormal Uterine Bleeding. [PDF]
Patil SS, Jadhav V, Pathak N.
europepmc +1 more source
A rat model of oral hormonal contraception: Effects on drug preference and gonadal function. [PDF]
Vasquez A +8 more
europepmc +1 more source
Venous thromboembolism in obese hormonal contraceptive users: a large national database study. [PDF]
Citla-Sridhar D +5 more
europepmc +1 more source

